Concerns about Moderna’s (Nasdaq: MRNA) post-COVID strategy have sparked a share price slide, following an ambivalent analysis from the firm’s flu vaccine program.
The global rollout of the Spikevax coronavirus vaccine generated tens of billions in revenue for the biotech, money which has been invested in further pipeline development.
The company’s flu vaccine is a major piece of that strategy, with executives anticipating a 2024 launch, just in time to offset declining Spikevax sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze